Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-22T21:07:43.377Z Has data issue: false hasContentIssue false
  • English
  • Français

Determination of Risk Factors Associated With Isolation of Linezolid-Resistant Strains of Vancomycin-Resistant Enterococcus

Published online by Cambridge University Press:  02 January 2015

Jason M. Pogue ,
David L. Paterson ,
A. William Pasculle  and
Brian A. Potoski
Jason M. Pogue
Affiliation:
Department of Pharmacy and Therapeutics, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
David L. Paterson
Affiliation:
Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
A. William Pasculle
Affiliation:
Clinical Microbiology Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Brian A. Potoski*
Affiliation:
Department of Pharmacy and Therapeutics, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
*
Division of Infectious Diseases, Suite 3A, Falk Medical Building; 3601 Fifth Avenue, Pittsburgh PA 15213 ([email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective.

To identify independent risk factors associated with isolation of linezolid-resistant, vancomycin-resistant Enterococcus (VRE).

Design.

A retrospective, case-case-control study.

Setting.

A tertiary care, academic medical center.

Methods.

VRE isolates from clinical cultures were retrospectively analyzed for linezolid resistance during our 18-month study period. Clinical data were obtained from electronic patient records, and the risk factors associated with isolation of linezolid-resistant VRE were determined by comparison of 2 case groups with a control group.

Results.

A total of 20% of the VRE isolates analyzed during the study period were linezolid resistant, and resistant isolates were most commonly recovered from the urine (40% of resistant isolates). Risk factors found to be associated with isolation of linezolid-resistant VRE were peripheral vascular disease and/or the receipt of a solid organ transplant, total parenteral nutrition, piperacillin-tazobactam, and/or cefepime. Only 25% of patients from whom linezolid-resistant VRE was isolated had previous linezolid exposure, and in the multivariate model this was not found to be a risk factor associated with the isolation of linezolid-resistant VRE.

Conclusions.

The results of this analysis suggest that there is horizontal transmission of linezolid-resistant VRE in our institution and highlight the need for improved infection control measures. Furthermore, the high incidence of linezolid-resistant VRE demands a reassessment of our empirical antibiotic selection for patients infected with VRE.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 28 , Issue 12 , December 2007 , pp. 1382 - 1388
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Pai, MP, Rodvold, KA, Schreckenberger, PC, Gonzales, RD, Petrolatti, JM, Quinn, JP. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2002;35:1269–1272.Google Scholar
2.Brauers, J, Kresken, M, Hafner, D, Shah, PM. Surveillance of linezolid resistance in Germany, 2001-2002. Clin Microbiol Infect 2005;11:39–46.CrossRefGoogle ScholarPubMed
3.Bonora, MG, Solbiati, M, Stepan, E, et al. Emergence of linezolid resistance in the vancomycin-resistance Enterococcus faecium multilocus sequence typing C1 lineage. J Clin Microbiol 2006;44:1153–1155.CrossRefGoogle Scholar
4.Mutnick, AH, Enne, V, Jones, RN. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. Ann Pharmacother 2003;37:769–773.Google Scholar
5.Burleson, BS, Ritchie, DJ, Micek, ST, Dunne, WM. Enterococcus faecalis resistant to linezolid: case series and review of the literature. Pharmacotherapy 2004;24:1225–1231.CrossRefGoogle ScholarPubMed
6.Swoboda, S, Fritz, S, Martignoni, ME, et al. Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report. J Antimicrob Chemother 2005;56:787–789.Google Scholar
7.Herrero, IA, Issa, NC, Patel, R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002;346 867–869CrossRefGoogle ScholarPubMed
8.Dobbs, TE, Patel, M, Waites, KB, Moser, SA, Stamm, AM, Hoesley, CJ. Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center. J Clin Microbiol 2006;44 3368–3370Google Scholar
9.Rahim, S, Pillai, SK, Gold, HS, Venkataraman, L, Inglima, K, Press, RA. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis 2003;36:e146–e148.CrossRefGoogle ScholarPubMed
10.Bonora, MG, Ligozzi, M, Luzzani, A, Solbiati, M, Stepan, E, Fontana, R. Emergence of linezolid resistance in Enterococcus faecium not dependent on linezolid treatment. Eur J Clin Microbiol Infect Dis 2006;25:197–198.CrossRefGoogle Scholar
11.Kainer, MA, Devasia, RA, Jones, TF, et al. Response to emerging infection leading to outbreak of linezolid-resistant enterococci. Emerg Infect Dis 2007;13:1024–1030.CrossRefGoogle ScholarPubMed
12.Herrero, IA, Issa, NC, Patel, R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002;346 867–869Google Scholar
13.Kumar, A, Roberts, D, Wood, KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589–1596.Google Scholar
14.Lodise, TP, McKinnon, PS, Tam, VH, Rybak, MJ. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant Enterococcus in a level 1 trauma center. Clin Infect Dis 2002;34 922–929CrossRefGoogle ScholarPubMed
15.Bar, K, Wisplinghoff, H, Wenzel, R, Bearman, GM, Edmond, MB. Systemic inflammatory response syndrome in adult patients with nosocomial bloodstream infections due to enterococci. BMC Infect Dis 2006;6 145–152Google Scholar
16.Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: 15th Informational Supplement. Wayne, PA: CLSI; 2004:M100–S15.Google Scholar
17.Harris, AD, Samore, MH, Lipsitch, M, Kaye, KS, Perencevich, E, Carmelli, Y. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, enterococci, and Escherichia coli. Clin Infect Dis 2002;34 1558–1563CrossRefGoogle ScholarPubMed
18.Kaye, KS, Harris, AD, Samore, M, Carmelli, Y. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol 2005;26:346–351.Google Scholar
19.Paterson, , DL, . Looking for risk factors for the acquisition of antibiotic resistance: a 21st-century approach. Clin Infect Dis 2002;34:1564–1567.Google Scholar
20.Harris, AD, Smith, D, Johnson, JA, Bradham, DD, Roghmann, MC. Risk Factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 2002;34:340–345.CrossRefGoogle ScholarPubMed
21.D'Agata, EM. Methodologie issues of case-control studies: a review of established and newly recognized limitations. Infect Control Hosp Epidemiol 2005;26:338–341.CrossRefGoogle Scholar
22.Dobbs, TE, Patel, M, Waites, KB, Moser, SA, Stamm, AM, Hoesley, CJ. Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center. J Clin Microbiol 2006;44 3368–3370Google Scholar
23.Jones, RN, Ross, JE, Fritsche, TR, Sader, HS. Oxazolidinone susceptibility pattern in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 2006;57:279–287.Google Scholar
24.Anderegg, TR, Sader, HS, Fritsche, TR, Ross, JE, Jones, RN. Trends in linezolid susceptibility patterns: report for the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. Int J Antimicrob Agents 2005;26:13–21.Google Scholar
25.Draghi, DC, Sheehan, DJ, Hogan, P, Sahm, DF. In Vitro activity of linezolid against key gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program. Antimicrob Agents Chemother 2005;49:5024–5032.CrossRefGoogle ScholarPubMed
26.Long, KS, Poehlsgaard, J, Kehrenberg, C, Schwarz, S, Vester, B. The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleurometins, and streptogramin a antibiotics. Antimicrob Agents Chemother 2006;50:2500–2505.Google Scholar